What Makes a Drug "Specialty" — and Why That Label Costs You More

The word "specialty" does not appear in the Federal Food, Drug, and Cosmetic Act. The FDA does not use it as a drug category. The Centers for Medicare and Medicaid Services does not maintain a federal list of drugs that carry it. There is no agency in the United States government that officially designates a drug as "specialty."

The designation is made by insurers and pharmacy benefit managers. And it is one of the most consequential classifications a drug can receive.

What the Label Actually Means

In practice, a drug is called specialty when it meets criteria that vary by payer but typically include some combination of the following: a monthly cost above approximately $600 to $700 (a threshold that has not been formally standardized but appears across multiple payer policies), complex administration or storage requirements, limited distribution channels, and a clinical profile that requires specialized patient management.

Biologics, gene therapies, IVIG, specialty infusion drugs, some oral oncology agents, and certain immunomodulators fall into this category on most commercial formularies. So do drugs like some newer oral treatments for multiple sclerosis, inflammatory bowel disease, and rare diseases.

What this means in practice: the drug is typically available only through a specialty pharmacy, not a retail chain. It almost always requires prior authorization before the insurer will cover it. And it is placed on the specialty tier of the formulary, which carries the highest cost-sharing structure in the plan.

No Standard, No Consistency

Because no federal definition governs the classification, the same drug can be labeled specialty on one plan and standard on another.

A 2021 analysis published in Health Affairs examining commercial formulary data found that specialty tier placement varied significantly across plans for the same drugs, with identical molecules assigned to different tiers, different cost-sharing structures, and different pharmacy channel requirements depending on the insurer and pharmacy benefit manager managing the benefit. The study found that patients in plans with stricter specialty tier definitions faced substantially higher out-of-pocket costs for the same therapies.

The PBM, which negotiates between drug manufacturers and health plans, plays a central role in these decisions. PBMs compile what are called preferred pharmacy networks, and specialty pharmacy channel requirements are frequently tied to these networks. Whether a drug must be dispensed through a specialty pharmacy, and which one, is often a function of the PBM's contracts, not the drug's clinical profile.

A patient who changes employers, and therefore changes health plans and PBMs, may find that a drug covered at a standard tier through their previous insurer now lands on the specialty tier, with a different pharmacy, different authorization requirements, and a substantially different cost-sharing obligation.

What the Specialty Tier Costs

Commercial health plans are not required to cap out-of-pocket spending at the specialty tier level for individual drugs. The ACA requires an overall annual out-of-pocket maximum, which in 2025 is $9,450 for individual coverage on marketplace plans, but that cap applies to aggregate spending across all services. It does not prevent a plan from assigning 25 to 30 percent coinsurance to a specialty drug with no drug-level cap.

For a biologic that lists at $4,000 per month, 25 percent coinsurance produces a patient obligation of $1,000 per month. Even with an annual out-of-pocket maximum, a patient reaches that ceiling primarily through specialty drug cost-sharing, after paying for it.

The Kaiser Family Foundation published data in 2022 showing that specialty tier cost-sharing varied widely across large employer plans, with coinsurance rates for specialty drugs ranging from 20 to 35 percent in the most common structures, and that roughly half of large employer plans had no specialty-tier specific cap below the overall OOP maximum. The practical consequence is that patients on specialty drugs, who are by definition managing serious, often chronic conditions, face among the highest cost-sharing burdens in the commercial insurance market.

Manufacturer copay assistance programs exist specifically because this cost-sharing structure would otherwise price patients out of drugs their physicians have prescribed. But those programs are not available to Medicare or Medicaid patients, and commercial plans have increasingly deployed accumulators and maximizers, which prevent manufacturer copay assistance from counting toward the patient's deductible and out-of-pocket maximum, extending the period over which the patient owes their full share before the plan absorbs the cost.

Medicare's 2025 Change

The Inflation Reduction Act changed the calculus for Medicare Part D patients beginning in 2025. Starting this year, Medicare Part D enrollees have a hard annual out-of-pocket cap of $2,000, applying to all covered drugs including specialty tier medications.

Before this change, Medicare Part D patients in the catastrophic phase of their benefit still owed a percentage of drug costs above the catastrophic threshold. The $2,000 cap eliminates that ongoing exposure. For a Medicare patient on a specialty drug costing $10,000 per month, out-of-pocket drug costs are now capped at $2,000 for the year, regardless of tier or coinsurance rate.

This is a significant protection for Medicare patients. It does not apply to commercial insurance, where the specialty tier coinsurance structure and the absence of drug-level caps remain unchanged.

Medicare patients should be aware that the $2,000 cap applies to covered drugs. If a drug is denied or requires an unresolved prior authorization, it is not covered, and the denial must be addressed through the appeal process before the cap applies.

Challenging the Classification

The specialty designation is not immutable. Formulary exception and tier exception processes exist specifically to contest cost-sharing assignments that are clinically unjustified.

A tier exception allows a member to request that a drug be covered at a lower tier's cost-sharing rate. For a specialty drug to qualify for a tier exception, the prescribing physician typically must document that the drugs available at lower tiers are clinically inappropriate, either because the patient has tried and failed them, because they are contraindicated given the patient's medical history, or because no lower-tier therapeutic equivalent exists.

CMS regulations require Medicare plans to have a formulary exception process and to respond to standard exception requests within 72 hours. Commercial plans under the ACA must also have an exceptions process, though the specific timelines and standards vary.

A separate pathway is a prior authorization appeal that contests not just the denial but the appropriateness of the specialty tier placement itself. This is more complex and typically requires physician documentation and potentially a peer-to-peer review, in which the prescribing physician speaks directly with the insurer's medical director. The success of this pathway depends heavily on how thoroughly the clinical case is documented.

The Word Doing a Lot of Work

"Specialty" sounds medical. It sounds like a clinical determination, something a physician or regulatory agency decided based on the drug's complexity or risk profile. It is not. It is a formulary management tool, applied by entities whose primary interest is in managing pharmaceutical benefit costs.

The consequences of the label, a higher-cost pharmacy channel, mandatory prior authorization, and coinsurance that can reach thousands of dollars per month with no drug-level cap, are real and substantial. Understanding that the label is applied by payers rather than regulators, and that it can be contested through the exception and appeal process, is not a technical distinction. For a patient receiving the bill, it is the difference between knowing there is a pathway and assuming there is none.

The Designation Is Reversible

The specialty classification, because it is made by a payer rather than a regulator, can be contested through the payer's own processes. The tier exception, the formulary exception, and the appeal are all mechanisms designed for this. They require documentation, they require physician involvement, and they are not guaranteed to succeed. But they exist.

The patients who navigate specialty drug costs most effectively are not the ones with the best insurance. They are the ones who understand that the word "specialty" on their Explanation of Benefits is a starting point for a conversation, not the end of one.

Sources: Health Affairs (2021), specialty tier placement variability across commercial formularies; Kaiser Family Foundation (2022), large employer plan specialty tier cost-sharing structures; CMS Medicare Part D Out-of-Pocket Cap, IRA implementation guidance 2025; CMS Formulary Exception Requirements, 42 CFR 423.578; ACA Section 2719, internal and external review requirements; CMS guidance on Part D specialty drug tier definitions.